Regulatory Post-Marketing Surveillance (rPMS) of Xolair® (Xolair® 150mg Powder for Solution for Injection, Xolair® 150mg/1ml Liquid in Pre-filled Syringe, Xolair® 75mg/0.5ml Liquid in Pre-filled Syringe) for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• Adults aged ≥18 years
• Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS)
• Patients prescribed with Xolair® as per the locally approved label information.
• Patients who provide written informed consent to participate in the study
Locations
Other Locations
Republic of Korea
Novartis Investigative Site
RECRUITING
Bundang Gu
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Backup
Novartis Pharmaceuticals
Time Frame
Start Date: 2023-01-12
Estimated Completion Date: 2025-01-31
Participants
Target number of participants: 112
Treatments
Xolair
patients who prescribed with Xolair according to the current label information in Korea.
Related Therapeutic Areas
Sponsors
Leads: Novartis Pharmaceuticals